UK Markets closed

Cizzle Biotechnology Holdings Plc (CIZ.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
1.9500+0.0500 (+2.63%)
At close: 04:21PM BST

Cizzle Biotechnology Holdings Plc

60 Gracechurch Street
6th Floor
London EC3V 0HR
United Kingdom

Full-time employees2

Key executives

NameTitlePayExercisedYear born
Mr. Allan John SymsExec. ChairmanN/AN/A1958
Dr. Dawn CoverleyFounder, Chief Scientific Officer & Non-Exec. DirectorN/AN/A1967
Mr. Nigel R. LeeFin. Director & DirectorN/AN/A1963
Mr. Morgan WilliamsHead of Commercialisation for Yorkshire Cancer Research and Board ObserverN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


Cizzle Biotechnology Holdings Plc engages in developing a blood test for the early detection of various forms of lung cancer. It develops CIZ1B protein gene and its potential as a diagnostic biomarker for detection and management of lung cancer. The company's CIZ1 promotes DNA replication and its organization and control. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings Plc is headquartered in London, the United Kingdom.

Corporate governance

Cizzle Biotechnology Holdings Plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.